2026 Could Be a Breakthrough Year for Medicine—Here's What to Watch

Medical researchers are predicting 2026 will mark a turning point for several groundbreaking treatments, with everything from customized gene therapies to bacteria-fighting cancer strategies moving from laboratory experiments to real-world patient care. Multiple clinical trials are set to deliver results that could reshape how doctors treat some of our most challenging diseases.

What Gene Therapy Breakthroughs Are Coming in 2026?

Gene therapy is experiencing its most exciting phase yet, with several revolutionary approaches reaching critical milestones. Baby KJ Muldoon became the first person to receive a customized CRISPR treatment that was tailored specifically to his rare genetic mutation, marking a shift from one-size-fits-all therapies to truly personalized medicine.

Unlike previous CRISPR treatments that required removing cells from the body for editing in a laboratory, KJ's treatment performed the genetic editing directly inside his body using messenger RNA (mRNA) technology. His doctors are now working with the Food and Drug Administration (FDA) to make these bespoke treatments more accessible to other patients.

• Huntington's Disease: Scientists are testing a gene therapy that may slow disease progression for the first time ever
• High Cholesterol: A CRISPR treatment is advancing through clinical trials to target genetic causes of elevated cholesterol
• Congenital Deafness: Gene therapy approaches are being developed to restore hearing in children born with genetic hearing loss
• Mitochondrial Diseases: Early trial results from the United Kingdom show promise for "mitochondrial donation" techniques that prevent mothers from passing harmful genetic mutations to their children

Which Clinical Trials Could Change Treatment Standards?

Several high-stakes clinical trials are expected to report results in the first half of 2026, with outcomes that could influence treatment approaches for millions of patients. Myles Minter, a biotech equity research analyst at William Blair, called one particular readout the "biggest biotech event of the entire year."

Novartis will publish results from its Phase III Lp(a)HORIZON study of pelacarsen, a treatment designed to lower lipoprotein(a) levels—a genetically determined risk factor for heart disease. This represents the first major test of whether reducing Lp(a) levels by 70% to 80% can actually prevent heart attacks and strokes. The results will be closely watched because multiple pharmaceutical companies including Amgen, Eli Lilly, AstraZeneca, and Merck are all developing similar treatments, with the market projected to reach over $8.5 billion by 2033.

Eli Lilly is expecting results from its TRAILRUNNER-ALZ 1 study of remternetug, positioned as the successor to its recently approved Alzheimer's drug Kisunla. The trial is testing both subcutaneous and intravenous formulations in more than 1,600 patients with early Alzheimer's disease, with the subcutaneous option potentially offering more convenient at-home treatment.

How Are Bacteria Affecting Cancer Treatment Success?

Cleveland Clinic researchers have made a surprising discovery that could explain why immunotherapy works for some cancer patients but not others. Two studies published simultaneously in Nature Cancer found that elevated levels of bacteria inside tumors suppress the immune response, making patients with head and neck squamous cell carcinoma resistant to immunotherapy treatments.

"These studies shift the focus of immunotherapy resistance research beyond tumor genetics to unexpected factors like the tumor microbiome," said Timothy Chan, chair of Cleveland Clinic's Department of Cancer Sciences and lead author of one of the papers.

The research team discovered that higher bacterial levels—regardless of the specific bacterial strains—weaken the immune system's ability to fight cancer. When they tested antibiotics in preclinical models, tumor size decreased and immune response improved. Conversely, adding bacteria made tumors more resistant to immunotherapy.

The mechanism involves neutrophils, white blood cells that normally fight infections but can suppress the immune system needed for immunotherapy to work effectively. Dr. Natalie Silver, director of Head and Neck Cancer Research at Cleveland Clinic, has launched a clinical trial funded by the American Cancer Society to test whether antibiotics can lower tumor bacteria levels and boost immunotherapy response in patients.

What Role Will Artificial Intelligence Play in 2026 Medicine?

Medical artificial intelligence (AI) is expected to mature significantly in 2026, moving from inflated expectations to proven real-world applications. Mass General Brigham researchers predict that AI will transition from the "Peak of Inflated Expectations" to the early "Slope of Enlightenment," meaning the technology will become more clinically validated and trustworthy as initial hype gives way to evidence-based results.

Next-generation spatial technologies will map every cell in human tissue with unprecedented detail, revealing how cellular neighborhoods influence function. When combined with AI analysis, these detailed tissue maps could unlock hidden patterns and pathways, transforming understanding of how tissues organize themselves in both healthy and diseased states.

"Human cellular models will become the backbone of precision neurology," explains Tracy Young Pearse, an investigator at Mass General Brigham. "Advances now allow us to study how genetic background influences disease and to measure therapeutic response in human-relevant systems, fundamentally transforming how we assess efficacy, stratify patients, and reduce risks in the clinical translation of new therapeutics."